Pyroxamide in Treating Patients With Advanced Cancer

• Status: Completed
• Trial end date: 2002-09-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed solid tumor or hematologic malignancy

• Disease that has failed standard therapies (e.g., surgery, radiotherapy, endocrine therapy, or chemotherapy) or for which no curative or life- prolonging therapy is available

• Measurable or clinically evaluable disease

• Elevated tumor marker is acceptable for evaluable disease

• No known carcinomatous meningitis, primary brain tumors, or metastatic brain disease

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 125,000/mm^3

• Hemoglobin at least 9.0 g/dL

Hepatic

• Bilirubin normal

• AST no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)

• PT no greater than 1.5 times ULN

Renal

• Creatinine normal

Other

• HIV-positive status allowed

• Prior malignancy allowed

• No severe physical or emotional illness that would preclude study participation

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No concurrent bone marrow growth factors

Chemotherapy

• See Disease Characteristics

• At least 4 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

• See Disease Characteristics

Radiotherapy

• See Disease Characteristics

• At least 4 weeks since prior wide-field radiotherapy and recovered

• At least 2 weeks since prior limited-field radiotherapy and recovered

• Recovered from prior radiotherapy

Surgery

• See Disease Characteristics

Other

• No other concurrent antitumor treatment